NCT03031392 is a clinical trial of Sensitivity test in Sensitivity, sponsored by Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain.

Who is sponsoring NCT03031392?

NCT03031392 is sponsored by Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain.

What drugs are being tested in NCT03031392?

Interventions in NCT03031392: Sensitivity test.

What condition does NCT03031392 study?

NCT03031392 studies Sensitivity, Peri-implant Mucositis, Peri-Implantational Loss, Peri-Implantitis.

Is NCT03031392 still recruiting?

NCT03031392 is currently completed. Last updated 11 May 2017.

Last reviewed 2017-05-11 · How we verify

NCT03031392

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sensitivity and Specificity of Peri-Implantitis-Related Parameters

Completed Last updated 11 May 2017

What this trial tests

trial testing Sensitivity test in Sensitivity in 141 participants. Completed in 2 April 2017.

Timeline

1 July 2016

Primary endpoint
1 April 2017

2 April 2017

Quick facts

Lead sponsor	Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
Status	Completed
Study type	OBSERVATIONAL
Enrollment	141
Start date	1 July 2016
Primary completion	1 April 2017
Estimated completion	2 April 2017
Sites	1 location across Spain

Drugs / interventions tested

Sensitivity test

Conditions studied

Sensitivity — all drugs for Sensitivity →
Peri-implant Mucositis — all drugs for Peri-implant Mucositis →
Peri-Implantational Loss — all drugs for Peri-Implantational Loss →
Peri-Implantitis — all drugs for Peri-Implantitis →

Sponsor

Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain — full company profile →

Who can join

Adults 18 to 80, any sex, with Sensitivity or Peri-implant Mucositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bleeding on probing demonstrated to have high specificity with certain level of sensitivity to detect periodontal disease. Again, understanding the weak hemidesmosome attachment to the implant surface is imperative to discern on the probe penetration extent and subsequent bleeding. In the presence of inflammation, bleeding should be present indicating high sensitivity when probing deeper sites; nevertheless the lack thereof in healthy condition does not seem to translate high specificity. In this sense, it is noteworthy to mention that the mucogingival shift after implant placement often decreases the presence of keratinized mucosa, triggering a greater inflammatory condition on the peri-implant tissues. Thereupon, bleeding on probing, although might reliably indicate presence of disease, it does not seem to be a suitable diagnostic parameter. On the other side, suppuration characterizes the necrosis of peri-implant tissues, being rich in polymorphonuclear cells and as such, a sensitive indicator of bone turnover. In this sense, it must be noted that, if detected in early stages where bone resorption has not occurred yet, it might be a consequence of a foreign body reaction (i.e., residual cement or floss). Therefore, in the diagnosis of peri-implantitis, radiographic examination must be always incorporated to the clinical assessment as the 'gold standard'. Hence, the aim of this case-control study was to assess the diagnostic accuracy of peri-implantitis-related clinical parameters compared to otherwise healthy dental implants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain trials

Trials by the same sponsor.

NCT06398288 — Adjunctive Use of Dermal Matrix to Compensate Dimensional Changes in the Reconstructive Therapy of Peri-implantitis · NA · recruiting
NCT05772078 — Compliance and Cumulative Interceptive Rate After Therapy of Peri-implantitis · completed
NCT06390124 — Reconstructive Therapy of Peri-implantitis with PDGF-BB (Gem-21) · Phase 4 · completed
NCT05615051 — Influence of Implant Surface Decontamination on the Reconstructive Outcomes of Peri-implantitis · NA · active not recruiting
NCT04410614 — Dimensional Changes of Free Epithelial Graft at Teeth and Implant Sites · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03031392 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain
Last refreshed: 11 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03031392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing